BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32140285)

  • 1. Outcomes and Safety of Outpatient Parenteral Antimicrobial Therapy in Select Children with Cystic Fibrosis.
    Com G; Agarwal A; Bai S; Hu Z; Goode G; McCarty H; Berlinski A
    Pediatr Allergy Immunol Pulmonol; 2019 Dec; 32(4):149-154. PubMed ID: 32140285
    [No Abstract]   [Full Text] [Related]  

  • 2. Outpatient parenteral antibiotic therapy (OPAT) for the management of bronchiectasis.
    Tu J; Al Harasi M; Pallin M; Daley C; Rogers BA; King PT
    Heliyon; 2023 Sep; 9(9):e19968. PubMed ID: 37809890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient Parenteral Antimicrobial Treatment for Non-Cystic Fibrosis Bronchiectasis Exacerbations: A Prospective Multicentre Observational Cohort Study.
    López-Cortés LE; Ayerbe-García R; Carrasco-Hernández L; Fraile-Ramos E; Carmona-Caballero JM; Quintana-Gallego E; Valido-Morales A; Praena J; Pachón-Diaz J;
    Respiration; 2019; 98(4):294-300. PubMed ID: 31288243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations.
    Pollak M; Shaw M; Wilson D; Solomon M; Ratjen F; Grasemann H
    Pediatr Pulmonol; 2021 Jul; 56(7):2036-2042. PubMed ID: 33830642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
    Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
    Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
    [No Abstract]   [Full Text] [Related]  

  • 6. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
    Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
    BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-Administered Outpatient Antimicrobial Infusion by Uninsured Patients Discharged from a Safety-Net Hospital: A Propensity-Score-Balanced Retrospective Cohort Study.
    Bhavan KP; Brown LS; Haley RW
    PLoS Med; 2015 Dec; 12(12):e1001922. PubMed ID: 26671467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
    West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
    J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use, appropriateness and outcomes of outpatient parenteral antimicrobial therapy.
    Hodgson KA; Huynh J; Ibrahim LF; Sacks B; Golshevsky D; Layley M; Spagnolo M; Raymundo CM; Bryant PA
    Arch Dis Child; 2016 Oct; 101(10):886-93. PubMed ID: 27166221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of adverse safety events and unscheduled care among an outpatient parenteral antimicrobial therapy (OPAT) patient cohort.
    Billmeyer KN; Ross JK; Hirsch EB; Evans MD; Kline SE; Galdys AL
    Ther Adv Infect Dis; 2023; 10():20499361231179668. PubMed ID: 37332294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient parenteral antimicrobial therapy (OPAT) for aortic vascular graft infection; a five-year retrospective evaluation.
    Allen N; Adam M; O'Regan G; Seery A; McNally C; McConkey S; Brown A; de Barra E
    BMC Infect Dis; 2021 Jul; 21(1):670. PubMed ID: 34243725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
    Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
    Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
    [No Abstract]   [Full Text] [Related]  

  • 13. Outpatient Versus Inpatient Intravenous Antimicrobial Therapy: A Population-Based Observational Cohort Study of Adverse Events and Costs.
    Staples JA; Ho M; Ferris D; Hayek J; Liu G; Tran KC; Sutherland JM
    Clin Infect Dis; 2022 Nov; 75(11):1921-1929. PubMed ID: 35439822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient Parenteral Antimicrobial Therapy in Pediatric Medicaid Enrollees.
    Goldman JL; Richardson T; Newland JG; Lee B; Gerber JS; Hall M; Kronman M; Hersh AL
    J Pediatric Infect Dis Soc; 2017 Mar; 6(1):65-71. PubMed ID: 26803327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
    Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
    Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
    [No Abstract]   [Full Text] [Related]  

  • 17. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.
    Heltshe SL; West NE; VanDevanter DR; Sanders DB; Beckett VV; Flume PA; Goss CH;
    Contemp Clin Trials; 2018 Jan; 64():35-40. PubMed ID: 29170074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without
    Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M; Kronman MP
    Ann Am Thorac Soc; 2022 Aug; 19(8):1320-1327. PubMed ID: 35289740
    [No Abstract]   [Full Text] [Related]  

  • 19. Discharge Delays and Costs Associated With Outpatient Parenteral Antimicrobial Therapy for High-Priced Antibiotics.
    Bianchini ML; Kenney RM; Lentz R; Zervos M; Malhotra M; Davis SL
    Clin Infect Dis; 2020 Oct; 71(7):e88-e93. PubMed ID: 31665269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
    Schultz A; McLeod C; Berry S; Marsh J; McKenzie A; Messer M; Wood J; Saville B; Jaffe A; Ranganathan S; Stick S; Wark P; Webb S; Snelling T
    Trials; 2023 Mar; 24(1):211. PubMed ID: 36949472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.